Insomnia drug improves work performance: Sanofi

Data show improvements in work performance in patients with chronic insomnia who are treated with the sleep aid Ambien (zolpidem tartrate), French pharmaceutical group Sanofi-Aventis said Wednesday

“Patients with chronic insomnia can have a higher frequency of work-related problems including absenteeism, an increased rate of accidents, difficulty performing duties and less job satisfaction,” Sanofi said in a statement.

These results, which are part of a larger study to evaluate the efficiency and safety of Ambien, were recently presented at the 20th annual U.S. psychiatric and mental health congress in Florida, Sanofi said in a statement.

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

New biomarkers may influence drug design and alternative treatments of cancer, study shows   UGA ecologist finds another cause of antibiotic resistance   New drug for neuroblastoma shows promise in phase I study   Baclofen shows promise in patients with alcohol-induced liver disease   Findings point to an ‘off switch’ for drug resistance in cancer   Sleep Loss Accelerates Brain Aging: Study   Stopping statins may benefit terminally ill patients   Cholesterol drug users may use pills as a license to overeat   Pfizer lung cancer drug beats chemo for previously untreated patients   Mass. General study identifies path to safer drugs for heart disease, cancer   Gates Foundation awards Notre Dame $23 million for malaria, dengue studies   Cancer drug protects against diabetes